PureTech to research Alzheimer's drugs based on 'brain drain...

US biotech PureTech Health is to develop therapies that are based on a new theory that neurological diseases such as Alzheimer’s are linked to drainage issues in the brain.

Hope for Alzheimer’s treatment after promising study results

Biogen and Eisai said their latest clinical study confirmed the amyloid hypothesis and might lead to the first drug successfully treating Alzheimer’s disease, instantly bumping their share

Eisai’s EMEA CEO Gary Hendler on why quality of life is key ...

Raising the bar in liver cancer therapy

Eisai accelerates dementia drug discovery research

Eisai is launching a special dementia discovery centre to boost development of next-generation medicines targeting forms of the condition, including Alzheimer’s disease.

Biogen’s Alzheimer’s drug, elenbecestat, shows early promise

A trial of Biogen’s Alzheimer’s disease drug elenbecestat has had promising results in mild to moderate forms of the disease.